S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Price, News & Analysis

$0.81
-0.18 (-18.18%)
(As of 03/28/2024 ET)
Today's Range
$0.81
$1.00
50-Day Range
$0.99
$1.45
52-Week Range
$0.81
$1.85
Volume
1.02 million shs
Average Volume
198,284 shs
Market Capitalization
$39.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Lucid Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.5% Upside
$2.75 Price Target
Short Interest
Healthy
2.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Lucid Diagnostics in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

733rd out of 939 stocks

Surgical & Medical Instruments Industry

79th out of 97 stocks

LUCD stock logo

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Stock Price History

LUCD Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Q4 2023 Lucid Diagnostics Inc Earnings Call
Lucid Diagnostics (LUCD) Set to Announce Earnings on Tuesday
The 3 Most Undervalued Penny Stocks to Buy in December
Lucid Diagnostics Inc LUCD
See More Headlines
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+239.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,170,000.00
Net Margins
-2,169.07%
Pretax Margin
-2,169.11%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.59 per share

Miscellaneous

Free Float
45,929,000
Market Cap
$39.07 million
Optionable
No Data
Beta
1.73
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Lishan Aklog M.D. (Age 58)
    Chairman & CEO
  • Mr. Shaun M. O'Neill M.B.A. (Age 41)
    President & COO
  • Mr. Dennis M. McGrath C.P.A. (Age 67)
    Chief Financial Officer
  • Dr. Sanford D. Markowitz M.D.
    Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Brian J. deGuzman M.D. (Age 59)
    Chief Compliance Officer
  • Mr. Michael Adam Gordon (Age 50)
    General Counsel & Secretary

LUCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings
or view top-rated stocks.

What is Lucid Diagnostics' stock price target for 2024?

2 analysts have issued 1-year price targets for Lucid Diagnostics' shares. Their LUCD share price targets range from $2.50 to $3.00. On average, they predict the company's stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 239.5% from the stock's current price.
View analysts price targets for LUCD
or view top-rated stocks among Wall Street analysts.

How have LUCD shares performed in 2024?

Lucid Diagnostics' stock was trading at $1.41 at the start of the year. Since then, LUCD shares have decreased by 42.6% and is now trading at $0.8099.
View the best growth stocks for 2024 here
.

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LUCD earnings forecast
.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) released its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company earned $1.04 million during the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative trailing twelve-month return on equity of 8,334.14%. During the same quarter last year, the firm earned ($0.22) EPS.

When did Lucid Diagnostics IPO?

Lucid Diagnostics (LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Who are Lucid Diagnostics' major shareholders?

Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Luminus Management LLC (1.73%), Nantahala Capital Management LLC (0.34%) and Virtu Financial LLC (0.05%).
View institutional ownership trends
.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUCD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners